ESR1 and breast carcinoma: The third SSP enzyme, phosphoserine phosphatase, is associated with poor therapeutic response of ER+ breast cancers to tamoxifen [177], and acts as an oncogene in various types of malignant tumors, including non-small-cell lung carcinoma (NSCLC) [178].